Webinar | August 29, 2022

Exothera Meets The High Demand For Viral Vector GMP Manufacturing With Integrated Solutions

Source: Cytiva

Exothera is a viral vector CDMO leveraging standard and innovative bioproduction platforms to rapidly deliver affordable viral vector-based vaccines and cell and gene therapies. Pall Corporation recently partnered with Exothera and supported them in the expansion of their manufacturing capabilities by adding a large-scale suspension-based manufacturing platform, from upstream through downstream processing of viral vectors of up to 2000 L.

In this webinar, we review the current market needs in terms of industrial-scale production of viral vector and share how moving to an integrated, end-to-end solution can help simplify and streamline your manufacturing process, thus reducing time to market.

access the Webinar!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Discovery Online? Subscribe today.

Subscribe to Drug Discovery Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Drug Discovery Online